| 5-FU | 5-Fluorouracil |
| AHR | Aryl hydrocarbon receptor |
| AP-1 | Activator protein-1 transcription factor |
| BAD | BCL2-associated agonist of cell death |
| BAX | BCL2-associated X |
| BCL2 | B-cell lymphoma 2 |
| CDC2 | Cyclin-dependent kinase 2 |
| CDC25C | Cell Division Cycle 25C |
| CDK2 | Cyclin D-dependent kinase 2 |
| CDK4 | Cyclin D-dependent kinase 4 |
| CDKN1A | Cyclin-dependent kinase inhibitor 1A |
| Chk2 | Checkpoint kinase 2 |
| DNA | Deoxyribonucleic Acid |
| EGFR | Epidermal growth factor receptor |
| EMT | Epithelial–mesenchymal transition |
| FADD | Fas-associated death domain |
| GRADE | Grading of Recommendations Assessment, Development, and Evaluation |
| HIF | Hypoxia-inducible factor |
| JNK | c-Jun N-terminal kinase |
| KMP | Kaempferol |
| MAPK | Mitogen-activated protein kinase |
| MMPs | Matrix metalloproteinases |
| mRNA | Messenger ribonucleic acid |
| mTOR | Mammalian target of rapamycin |
| Nrf2 | Nuclear factor erythroid 2-related factor 2 |
| PKB | Protein kinase B, also known as AKT |
| ROS | Reactive oxygen species |
| Smad2 | Mothers against decapentaplegic homolog 2 |
| Smad4 | Mothers against decapentaplegic homolog 4 |
| STAT | Signal transducer and activator of transcription |
| TFEB | Transcription factor EB |
| TGF-β1 | Transforming growth factor-β1 |
| VEGF | Vascular endothelial growth factor |